The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Metabolism
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1430533
Genetically predicted metabolites mediate the association between lipidome and Malignant melanoma of skin
Provisionally accepted- 1 The First Clinical College of Chongqing Medical University, Chongqing, 400016, People’s Republic of China, Chongqing, China
- 2 First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
- 3 First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
Objective: To investigate the causal relationship between lipidome and Malignant melanoma of skin (MMOS), while identifying and quantifying the role of metabolites as potential mediators. Methods: A two-sample Mendelian randomization (MR) analysis of lipid species (n=7174) and MMOS was performed using pooled data from genome-wide association studies (GWAS). In addition, we quantified the proportion of metabolite-mediated lipidome effects on MMOSby two-step MR. Results: This study identified potential causal relationships between 11 lipids and MMOS, and 40 metabolites and MMOS, respectively. Phosphatidylethanolamine (18:0_18:2) levels mined from 179 lipids by MR Analysis increased the risk of MMOS (OR: 1.962; 95%CI:1.298,2.964; P=0.001). There is no strong evidence for a relationship between genetically predicted MMOS and Phosphatidylethanolamine (18:0_18:2) levels (P=0.628). The proportion of gene predictions for Phosphatidylethanolamine (18:0_18:2) levels mediated by 1-stearoyl-GPI (18:0) levels was 12.40%. Conclusion: This study identifies 1-stearoyl-GPI (18:0) levels as a potential mediator that may mediate the causal relationship between Phosphatidylethanolamine (18:0_18:2) levels and MMOS, This provides direction for the investigation of MMOS, but further research of other possible potential mediators is still needed.
Keywords: Malignant melanoma of skin, Lipidome, Mendelian randomization, Metabolites, Mediator
Received: 10 May 2024; Accepted: 26 Aug 2024.
Copyright: © 2024 Wu, Ma and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zhenyu Liu, First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, Chongqing Municipality, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.